文献速递免疫规划

适配JN.1或KP.2的mRNA-1273疫苗在小鼠中诱导针对SARS-CoV-2 JN.1亚谱系的交叉中和反应

mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
PubMed 文献 · Vaccine · 2025-03-07

研究评估编码JN.1(mRNA-1273.167)或KP.2(mRNA-1273.712)刺突蛋白的单价mRNA-1273疫苗,与单价XBB.1.5疫苗(mRNA-1273.815)比较,在未免疫小鼠两剂基础系列或既往两剂原始株mRNA-1273免疫小鼠的加强(第三剂)中的免疫原性。JN.1或KP.2匹配疫苗均诱导对匹配株的强中和抗体滴度,并有效交叉中和KP.3、LA.2和XEC,但不中和抗原距离较远的XBB.1.5。

要点

  • JN.1或KP.2匹配的mRNA-1273疫苗在基础免疫和加强免疫中均诱导对匹配株的强中和抗体。
  • 上述疫苗可交叉中和JN.1相关亚谱系KP.3、LA.2和重组株XEC,但不中和XBB.1.5。
  • 数据提示JN.1与KP.2/JN.1相关亚谱系之间刺突差异较少、抗原性相似。

核心结论

  • 含JN.1和KP.2的mRNA-1273疫苗能中和匹配变异株并交叉中和JN.1相关亚谱系KP.3、LA.2和XEC。
  • 数据提示已获批的JN.1和KP.2 mRNA疫苗可能随JN.1谱系进一步演化而继续提供保护。

研究设计与样本

  • 评估两种更新单价含变异株mRNA-1273疫苗(编码JN.1的mRNA-1273.167和编码KP.2的mRNA-1273.712)与单价XBB.1.5疫苗(mRNA-1273.815)的免疫原性。
  • 疫苗在未免疫小鼠中作为两剂基础系列接种,或在既往接受两剂原始株mRNA-1273基础系列的小鼠中作为加强(第三)剂接种。

主要发现

  • JN.1或KP.2匹配疫苗基础系列免疫诱导对匹配株的强中和抗体滴度,并有效交叉中和KP.3、LA.2和XEC,但不中和抗原距离较远的XBB.1.5。
  • JN.1和KP.2匹配疫苗作为加强(第三)剂增加对相应株和JN.1相关亚谱系的中和滴度,但不增加对XBB.1.5的滴度。
  • 数据提示JN.1与KP.2/JN.1相关亚谱系之间刺突差异相对较少、抗原性相似。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The continued diversification of SARS-CoV-2 omicron lineage has given rise to the JN.1 variant and descendant strains (KP.2, KP.3, and XEC) that have prolonged the JN.1 infection wave. JN.1 and KP.2 show decreased susceptibility to neutralization sera in recipients of XBB.1.5 vaccine boosters, supporting the recent authorization of JN.1- and KP.2-matched mRNA vaccines in the United States, Europe, and other regions. We evaluated the immunogenicity of two updated monovalent variant-containing formulations of mRNA-1273 vaccines encoding the spike protein of the omicron subvariants JN.1 (mRNA-1273.167) and KP.2 (mRNA-1273.712) as compared with the monovalent XBB.1.5 vaccine (mRNA-1273.815). The vaccines were administered either as a two-dose primary series in naive mice or as a booster (third) dose in mice previously immunized with two-dose primary series of mRNA-1273 (ancestral strain). The neutralizing antibody response elicited by these vaccines against JN.1 subvariants (KP.3 and LA.2) and the recombinant strain (XEC), which achieved dominance in the United States during late 2024, was evaluated. Primary series immunization with either JN.1- or KP.2-matched vaccine elicited robust neutralizing antibody titers against the matched strains and effectively cross-neutralized KP.3, LA.2, and XEC, but not the antigenically distant XBB.1.5. Similarly, JN.1- and KP.2-matched vaccines administered as a booster (third) dose increased titers against the corresponding strains and JN.1-related subvariants, but not against XBB.1.5. These data suggest these strains are antigenically similar with relatively few spike differences between JN.1 and KP.2/JN.1-related subvariants. Our results demonstrate the potency of JN.1- and KP.2-containing mRNA-1273 vaccines in neutralizing the matched variants and their utility in cross-neutralizing JN.1-related subvariants KP.3, LA.2, and XEC. Taken together, these data suggest that the licensed JN.1 and KP.2 mRNA vaccines are likely to continue to protect against the emerging strains as the JN.1 lineage further evolves.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee DW, Nasir A, Elbashir S, et al. mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice. Vaccine. 2025. PMID: 40056804. doi:10.1016/j.vaccine.2025.126961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。